Alexander J. Van Akkooi
Expertise in
5
conditions

Alexander J. Van Akkooi

Amsterdam, NH, NL 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
5
conditions
Amsterdam, NH, NL 
OverviewLocationsClinical Research

Overview

Alexander Van Akkooi practices in Amsterdam, Netherlands. Mr. Van Akkooi is highly rated in 5 conditions, according to our data. His top areas of expertise are Melanoma, Merkel Cell Carcinoma, Oral Herpes, Neuroendocrine Tumor, and Lymphadenectomy.

His clinical research consists of co-authoring 228 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Amsterdam, NH 1066CX, Netherlands
Other Locations
Sittard, LI, Netherlands
Utrecht, UT 3584CS, Netherlands
Netherlands
Rotterdam, ZH, Netherlands

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase Ib/II Randomized Double-blind Placebo Controlled Trial Evaluating the Effect of Nivolumab for Patients With In-transit Melanoma Metastases Treated With Isolated Limb Perfusion - the NivoILP Trial
A Phase Ib/II Randomized Double-blind Placebo Controlled Trial Evaluating the Effect of Nivolumab for Patients With In-transit Melanoma Metastases Treated With Isolated Limb Perfusion - the NivoILP Trial
Enrollment Status: Recruiting
Publish Date: April 25, 2024
Intervention Type: Drug, Procedure
Study Drug: Nivolumab
Study Phase: Phase 1/Phase 2
Minitub: Prospective Registry of Sentinel Node (SN) Positive Melanoma Patients With Minimal SN Tumor Burden Who Undergo Completion Lymph Node Dissection (CLND) or Nodal Observation
Minitub: Prospective Registry of Sentinel Node (SN) Positive Melanoma Patients With Minimal SN Tumor Burden Who Undergo Completion Lymph Node Dissection (CLND) or Nodal Observation
Enrollment Status: Active_not_recruiting
Publish Date: November 28, 2023
Adjuvant Pegylated-Interferon-alpha2b (SylatronTM) for 2 Years Versus Observation in Patients With an Ulcerated Primary Cutaneous Melanoma With T(2-4)bN0M0: a Randomized Phase III Trial of the EORTC Melanoma Group.
Adjuvant Pegylated-Interferon-alpha2b (SylatronTM) for 2 Years Versus Observation in Patients With an Ulcerated Primary Cutaneous Melanoma With T(2-4)bN0M0: a Randomized Phase III Trial of the EORTC Melanoma Group.
Enrollment Status: Unknown
Publish Date: March 04, 2019
Intervention Type: Biological
Study Drug: PEG IFN Alfa-2b
Study Phase: Phase 3
View 2 Less Clinical Trial

228 Total Publications

Reduction in surgical interventions in melanoma.
Reduction in surgical interventions in melanoma.
Journal: European journal of cancer (Oxford, England : 1990)
Published: March 18, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Van Akkooi's expertise for a condition
ConditionClose
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile